Research News
Driven by a desire to make a meaningful impact on public health, National Glaucoma Research grant recipient Dr. Bingrui Wang is developing glaucoma prediction technology and tools for early detection.
In glaucoma, problems with mitochondria—a source of cell energy—can damage neurons that carry visual information from the eyes to the brain. Adriana Di Polo, PhD, is testing small molecule drugs that may prevent this damage and boost energy production in these neurons.
A new BrightFocus-funded glaucoma vision research study suggests that Black and Asian people receive a critical glaucoma screening test less frequently than others, which could delay sight-saving treatment.
The U.S. Food and Drug Administration has approved a new treatment for glaucoma, iDose® TR (travoprost intracameral implant, 75 mcg). iDose TR is a first-of-its kind treatment that is designed to provide up to three years of 24/7, continuous drug therapy directly inside the eye, helping people with glaucoma take control over the elevated eye pressure associated with this vision disease.
In a first of its kind study, BrightFocus-funded researchers have identified a possible new way to improve drugs to treat glaucoma by studying a tiny part of the eye’s drainage system that plays a major role in eye pressure.
Researchers have found a way to block a “master switch” in the eye and the brain that controls inflammation, introducing a possible target for combatting glaucoma and other neurodegenerative diseases.
Harnessing the power of artificial intelligence, researchers have identified nearly 200 previously unknown DNA regions linked to a risk of developing glaucoma, findings that could lead to new ways of preventing the disease.
Initial study results of an innovative glaucoma therapy involving eye implants have yielded positive results, and a Phase 2 clinical trial of this exciting potential treatment has begun.
BrightFocus-funded research offers the potential to restore vision loss due to glaucoma using cell replacement therapy.
A team of BrightFocus-funded scientists has proposed a new explanation and possible new target for treatment in glaucoma that’s unrelated to the common culprit of eye pressure.
